ThermoGenesis's FDA-cleared pro-healing cell tech to hit US later this year
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for the Res-Q 60 system developed by stem cell specialist ThermoGenesis. The technology may now be used to prepare autologous platelet-rich plasma (PRP) from a patient's blood sample at the point of care. The PRP, a source of growth factors which has been shown to enhance healing, is mixed with autograft and/or allograft bone prior to application to a bone defect. The Rancho Cordova, California company says it hopes to form US distribution agreements "in the coming months", and begin selling Res-Q 60 later this year. The firm says that PRP is also potentially applicable to other conditions, including orthopaedic and cardiovascular indications.